“…Although viral vectors can efficiently deliver therapeutic nucleotides into cells, the clinical application of these vectors is associated with considerable safety and immunogenicity risks 3, 4. More recently, cationic polymers have been increasingly investigated as safer alternatives for gene therapy 5–8 because of their potential advantages, such as the absence of a specific immune response, the large DNA loading capacity, and the flexibility to design a carrier with well‐defined structural and chemical properties on a large scale 9–12.…”